HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

fluindione

structure
Also Known As:
2-(4-fluorophenyl)-1,3-indanedione; Previscan; Procter & Gamble brand of fluindione; 1H-Indene-1,3(2H)-dione, 2-(4-fluorophenyl)-
Networked: 44 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Golmard, Jean-Louis: 2 articles (04/2014 - 01/2012)
2. Lacut, Karine: 2 articles (04/2014 - 03/2012)
3. Siguret, Virginie: 2 articles (04/2014 - 01/2012)
4. Loriot, Marie-Anne: 2 articles (04/2014 - 01/2012)
5. Moreau, Caroline: 2 articles (04/2014 - 01/2012)
6. Andro, Marion: 2 articles (04/2014 - 03/2012)
7. Roth, B: 2 articles (03/2012 - 12/2005)
8. Becquemont, Laurent: 2 articles (03/2012 - 01/2012)
9. Tortel, M-C: 2 articles (03/2012 - 12/2005)
10. Lechat, P: 2 articles (01/2001 - 11/2000)

Related Diseases

1. Atrial Fibrillation
01/01/2001 - "Evaluation of the preventive efficacy against nonfatal thromboembolic events and vascular deaths of the combination of the oral anticoagulant fluindione and aspirin (100 mg) in patients with high-risk atrial fibrillation. "
11/01/2000 - "[Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. "
01/01/2001 - "Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. "
12/01/2003 - "The prevention of the thromboembolic complications of chronic atrial fibrillation remains a therapeutic challenge because they cannot be completely suppressed by vitamin K antagonists with a target international normalized ratio between 2 and 3. Evaluation of the combination at that international normalized ratio level with antiplatelet therapy was the aim of the placebo-controlled double-blind Fluindione Fibrillation Auriculaire, Aspirine et Contraste Spontané (FFAACS) study with fluindione (as anticoagulant) and aspirin (100 mg) in patients with chronic atrial fibrillation at high risk of thromboembolic complications. "
04/01/2015 - "We extracted data for adults (aged ≥18 years) with non-valvular atrial fibrillation who received their first prescription for a vitamin K antagonist (fluindione, warfarin, or acenocoumarol) between Jan 1, 2011, and Nov 30, 2012, and who were either switched to a NOAC (dabigatran or rivaroxaban) or maintained on the vitamin K antagonist. "
2. Thrombosis (Thrombus)
3. Nephritis
4. Interstitial Nephritis (Tubulointerstitial Nephritis)
5. Hypersensitivity (Allergy)

Related Drugs and Biologics

1. Aspirin (Acetylsalicylic Acid)
2. Vitamin K
3. Collagen
4. fluindione
5. Warfarin (Coumadin)
6. Acenocoumarol
7. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
8. Heparin (Liquaemin)
9. 1,2-indanedione
10. Cytochrome P-450 CYP1A2 (CYP1A2)

Related Therapies and Procedures

1. Transplantation (Transplant Recipients)
2. Home Nursing (Nursing, Home)
3. Aftercare (After-Treatment)